1230105

Novartis Pharmaceuticals Corporation — FEI 2210396

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
June 27, 2024
Fiscal Year
2024
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
East Hanover, NJ (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)